Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt 1.06
CFN's Cash to Debt is ranked higher than
70% of the 315 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.11 vs. CFN: 1.06 )
CFN' s 10-Year Cash to Debt Range
Min: 0.61   Max: 1.49
Current: 1.06

0.61
1.49
Equity to Asset 0.56
CFN's Equity to Asset is ranked higher than
68% of the 309 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.60 vs. CFN: 0.56 )
CFN' s 10-Year Equity to Asset Range
Min: 0.56   Max: 0.65
Current: 0.56

0.56
0.65
F-Score: 6
Z-Score: 2.73
M-Score: -2.43
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) 16.16
CFN's Operating margin (%) is ranked higher than
87% of the 311 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 11.19 vs. CFN: 16.16 )
CFN' s 10-Year Operating margin (%) Range
Min: 12.35   Max: 17.44
Current: 16.16

12.35
17.44
Net-margin (%) 10.85
CFN's Net-margin (%) is ranked higher than
83% of the 311 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 7.12 vs. CFN: 10.85 )
CFN' s 10-Year Net-margin (%) Range
Min: 5.74   Max: 15.8
Current: 10.85

5.74
15.8
ROE (%) 7.74
CFN's ROE (%) is ranked higher than
75% of the 309 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 8.39 vs. CFN: 7.74 )
CFN' s 10-Year ROE (%) Range
Min: 3.82   Max: 13.35
Current: 7.74

3.82
13.35
ROA (%) 4.74
CFN's ROA (%) is ranked higher than
78% of the 316 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.40 vs. CFN: 4.74 )
CFN' s 10-Year ROA (%) Range
Min: 2.38   Max: 8.18
Current: 4.74

2.38
8.18
ROC (Joel Greenblatt) (%) 67.54
CFN's ROC (Joel Greenblatt) (%) is ranked higher than
94% of the 315 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 21.21 vs. CFN: 67.54 )
CFN' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 37.79   Max: 119.44
Current: 67.54

37.79
119.44
Revenue Growth (%) 5.70
CFN's Revenue Growth (%) is ranked higher than
75% of the 284 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 6.10 vs. CFN: 5.70 )
CFN' s 10-Year Revenue Growth (%) Range
Min: 0   Max: 5.7
Current: 5.7

0
5.7
EBITDA Growth (%) 7.90
CFN's EBITDA Growth (%) is ranked higher than
76% of the 240 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 7.10 vs. CFN: 7.90 )
CFN' s 10-Year EBITDA Growth (%) Range
Min: 0   Max: 8.9
Current: 7.9

0
8.9
EPS Growth (%) 14.10
CFN's EPS Growth (%) is ranked higher than
82% of the 244 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 8.60 vs. CFN: 14.10 )
CFN' s 10-Year EPS Growth (%) Range
Min: 0   Max: 34.2
Current: 14.1

0
34.2
» CFN's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2013

CFN Guru Trades in Q4 2013

Steven Cohen 683,742 sh (+1147.36%)
Paul Tudor Jones 238,700 sh (+138.7%)
Robert Olstein 219,000 sh (+34.36%)
Diamond Hill Capital 98,438 sh (+9.78%)
Joel Greenblatt 205,291 sh (+4.88%)
First Pacific Advisors 4,551,800 sh (+0.27%)
Steven Romick 4,325,000 sh (unchged)
Vanguard Health Care Fund 4,970,354 sh (unchged)
Jeremy Grantham 14,556 sh (-14.66%)
Pioneer Investments 339,644 sh (-47.65%)
Jim Simons 487,600 sh (-67.69%)
» More
Q1 2014

CFN Guru Trades in Q1 2014

Ray Dalio 22,200 sh (New)
Diamond Hill Capital 213,940 sh (+117.33%)
Robert Olstein 222,000 sh (+1.37%)
First Pacific Advisors 4,568,100 sh (+0.36%)
Steven Romick 4,325,000 sh (unchged)
Vanguard Health Care Fund 4,970,354 sh (unchged)
Pioneer Investments Sold Out
Jeremy Grantham Sold Out
Jim Simons Sold Out
Steven Cohen 465,370 sh (-31.94%)
Joel Greenblatt 41,513 sh (-79.78%)
Paul Tudor Jones 18,292 sh (-92.34%)
» More
Q2 2014

CFN Guru Trades in Q2 2014

Larry Robbins 1,909,705 sh (New)
Jim Simons 125,000 sh (New)
Louis Moore Bacon 109,695 sh (New)
Paul Tudor Jones 361,300 sh (+1875.18%)
Vanguard Health Care Fund 5,661,354 sh (+13.9%)
Diamond Hill Capital 242,594 sh (+13.39%)
Steven Cohen 47,800 sh (unchged)
Ray Dalio Sold Out
Robert Olstein 208,000 sh (-6.31%)
First Pacific Advisors 3,801,500 sh (-16.78%)
Steven Romick 3,580,000 sh (-17.23%)
Joel Greenblatt 4,642 sh (-88.82%)
» More
Q3 2014

CFN Guru Trades in Q3 2014

Steven Romick 3,090,000 sh (-13.69%)
» More
» Details

Insider Trades

Latest Guru Trades with CFN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Joel Greenblatt 2014-06-30 Reduce -88.82%0.02%$38.16 - $44.37 $ 56.938%4642
Ray Dalio 2014-06-30 Sold Out 0.01%$38.16 - $44.37 $ 56.938%0
Joel Greenblatt 2014-03-31 Reduce -79.78%0.15%$38.52 - $41.71 $ 56.941%41513
Ray Dalio 2014-03-31 New Buy0.01%$38.52 - $41.71 $ 56.941%22200
Robert Olstein 2013-12-31 Add 34.36%0.31%$36.73 - $40.24 $ 56.946%219000
Lee Ainslie 2013-06-30 Sold Out 0.67%$33.21 - $38.17 $ 56.961%0
Joel Greenblatt 2013-06-30 Add 53.73%0.1%$33.21 - $38.17 $ 56.961%180890
Chris Davis 2013-06-30 Sold Out $33.21 - $38.17 $ 56.961%0
Robert Olstein 2013-03-31 Reduce -20.94%0.27%$28.58 - $34.99 $ 56.978%185000
Joel Greenblatt 2013-03-31 Add 137.86%0.12%$28.58 - $34.99 $ 56.978%117665
Lee Ainslie 2012-12-31 Reduce -68.04%1.43%$26.54 - $29.05 $ 56.9105%1811353
Robert Olstein 2012-12-31 Reduce -21.48%0.34%$26.54 - $29.05 $ 56.9105%234000
Joel Greenblatt 2012-12-31 Add 37.36%0.02%$26.54 - $29.05 $ 56.9105%49469
David Einhorn 2012-09-30 Sold Out 1.9%$24.01 - $28.63 $ 56.9118%0
Lee Ainslie 2012-09-30 Reduce -37.47%1.27%$24.01 - $28.63 $ 56.9118%5666718
Joel Greenblatt 2012-09-30 Reduce -65.35%0.13%$24.01 - $28.63 $ 56.9118%36014
John Keeley 2012-09-30 Sold Out 0.11%$24.01 - $28.63 $ 56.9118%0
David Einhorn 2012-06-30 Reduce -55.93%2.74%$23.9 - $27.1 $ 56.9125%4588902
Andreas Halvorsen 2012-06-30 Sold Out 1.2%$23.9 - $27.1 $ 56.9125%0
Lee Ainslie 2012-06-30 Add 6.35%0.2%$23.9 - $27.1 $ 56.9125%9062564
Joel Greenblatt 2012-06-30 Add 379.76%0.16%$23.9 - $27.1 $ 56.9125%103931
Dodge & Cox 2012-06-30 Sold Out 0.01%$23.9 - $27.1 $ 56.9125%0
Andreas Halvorsen 2012-03-31 Reduce -43.57%1.18%$22.82 - $26.2 $ 56.9146%5817571
Lee Ainslie 2012-03-31 Add 8.9%0.26%$22.82 - $26.2 $ 56.9146%8521463
Robert Olstein 2012-03-31 Add 10.49%0.14%$22.82 - $26.2 $ 56.9146%316000
Joel Greenblatt 2012-03-31 New Buy0.05%$22.82 - $26.2 $ 56.9146%21663
John Keeley 2012-03-31 Add 30.15%0.02%$22.82 - $26.2 $ 56.9146%186000
Lee Ainslie 2011-12-31 Add 122.58%1.54%$23.11 - $25.97 $ 56.9132%7824682
Andreas Halvorsen 2011-12-31 Add 36.2%0.72%$23.11 - $25.97 $ 56.9132%10308891
George Soros 2011-12-31 Sold Out 0.01%$23.11 - $25.97 $ 56.9132%0
Ray Dalio 2011-12-31 Sold Out 0.01%$23.11 - $25.97 $ 56.9132%0
Dodge & Cox 2011-12-31 Reduce -24.19%$23.11 - $25.97 $ 56.9132%183565
David Einhorn 2011-09-30 Add 34.38%1.68%$22.26 - $28.14 $ 56.9124%12799424
Andreas Halvorsen 2011-09-30 Add 262.68%1.52%$22.26 - $28.14 $ 56.9124%7569191
Lee Ainslie 2011-09-30 New Buy1.18%$22.26 - $28.14 $ 56.9124%3515524
Dodge & Cox 2011-09-30 Reduce -84.91%0.04%$22.26 - $28.14 $ 56.9124%242140
George Soros 2011-09-30 Add 32.61%$22.26 - $28.14 $ 56.9124%12200
Ray Dalio 2011-09-30 Add 89.2%$22.26 - $28.14 $ 56.9124%27150
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 29.00
CFN's P/E(ttm) is ranked higher than
76% of the 327 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 34.70 vs. CFN: 29.00 )
CFN' s 10-Year P/E(ttm) Range
Min: 7.6   Max: 39.94
Current: 29

7.6
39.94
P/B 2.18
CFN's P/B is ranked higher than
76% of the 327 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.99 vs. CFN: 2.18 )
CFN' s 10-Year P/B Range
Min: 0.88   Max: 2.2
Current: 2.18

0.88
2.2
P/S 3.14
CFN's P/S is ranked higher than
62% of the 327 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.90 vs. CFN: 3.14 )
CFN' s 10-Year P/S Range
Min: 1.13   Max: 3.17
Current: 3.14

1.13
3.17
PFCF 20.47
CFN's PFCF is ranked higher than
88% of the 327 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 84.15 vs. CFN: 20.47 )
CFN' s 10-Year PFCF Range
Min: 5.99   Max: 35.57
Current: 20.47

5.99
35.57
EV-to-EBIT 18.29
CFN's EV-to-EBIT is ranked higher than
84% of the 327 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 25.53 vs. CFN: 18.29 )
CFN' s 10-Year EV-to-EBIT Range
Min: 8.3   Max: 19.1
Current: 18.29

8.3
19.1
PEG 3.40
CFN's PEG is ranked higher than
87% of the 327 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9999.00 vs. CFN: 3.40 )
CFN' s 10-Year PEG Range
Min: 0.94   Max: 3.66
Current: 3.4

0.94
3.66
Shiller P/E 33.42
CFN's Shiller P/E is ranked higher than
78% of the 327 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 224.47 vs. CFN: 33.42 )
CFN' s 10-Year Shiller P/E Range
Min: 23.27   Max: 33.66
Current: 33.42

23.27
33.66
Current Ratio 3.11
CFN's Current Ratio is ranked higher than
79% of the 310 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.74 vs. CFN: 3.11 )
CFN' s 10-Year Current Ratio Range
Min: 2.9   Max: 5.29
Current: 3.11

2.9
5.29
Quick Ratio 2.74
CFN's Quick Ratio is ranked higher than
82% of the 310 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.82 vs. CFN: 2.74 )
CFN' s 10-Year Quick Ratio Range
Min: 2.17   Max: 4.64
Current: 2.74

2.17
4.64

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 11.05
CFN's Price/Tangible Book is ranked lower than
54% of the 327 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 6.70 vs. CFN: 11.05 )
CFN' s 10-Year Price/Tangible Book Range
Min: 4.18   Max: 8.63
Current: 11.05

4.18
8.63
Price/DCF (Projected) 1.29
CFN's Price/DCF (Projected) is ranked higher than
86% of the 327 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.30 vs. CFN: 1.29 )
CFN' s 10-Year Price/DCF (Projected) Range
Min: 1.01   Max: 1.01
Current: 1.29

Price/Median PS Value 1.83
CFN's Price/Median PS Value is ranked lower than
57% of the 327 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.10 vs. CFN: 1.83 )
CFN' s 10-Year Price/Median PS Value Range
Min: 0.82   Max: 1.43
Current: 1.83

0.82
1.43
Price/Peter Lynch Fair Value 3.62
CFN's Price/Peter Lynch Fair Value is ranked higher than
81% of the 327 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9999.00 vs. CFN: 3.62 )
CFN' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.97   Max: 2.83
Current: 3.62

0.97
2.83
Price/Graham Number 3.72
CFN's Price/Graham Number is ranked higher than
69% of the 327 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 6.13 vs. CFN: 3.72 )
CFN' s 10-Year Price/Graham Number Range
Min: 1.71   Max: 3.03
Current: 3.72

1.71
3.03
Earnings Yield (Greenblatt) 5.50
CFN's Earnings Yield (Greenblatt) is ranked higher than
74% of the 231 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.50 vs. CFN: 5.50 )
CFN' s 10-Year Earnings Yield (Greenblatt) Range
Min: 5.2   Max: 12.1
Current: 5.5

5.2
12.1
Forward Rate of Return (Yacktman) 11.05
CFN's Forward Rate of Return (Yacktman) is ranked higher than
84% of the 274 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.38 vs. CFN: 11.05 )
CFN' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 11.6   Max: 26.8
Current: 11.05

11.6
26.8

Business Description

Industry: Medical Instruments & Equipment » Medical Instruments & Supplies
Compare: » details
Traded in other countries:TCF.Germany
CareFusion Corp., a Delaware corporation was incorporated on January 14, 2009. The Company is a medical technology company that offers products and services in the areas of medication management, infection prevention, operating room effectiveness, respiratory care and surveillance and analytics. Its main product brands include Alaris intravenous ('IV') infusion systems; Pyxis automated medication dispensing and supply management systems; AVEA, Vela and LTV Series respiratory ventilators; ChloraPrep skin antiseptic products; MaxGuard, MaxPlus and SmartSite needle-free IV infusion disposable sets and accessories; V. Mueller and Snowden-Pencer open surgical and laparoscopic instrumentation; AirLife nebulizers, ventilator circuits and other disposables used for providing respiratory therapy; Jaeger and SensorMedics cardiopulmonary diagnostic equipment; and MedMined software and surveillance services. The Company's main competitors in its Medical Systems segment include Baxter International; B. Braun; Fresenius Kabi; Hospira; Omnicell; McKesson; Dräger; and MAQUET. The Company's competitors in its Procedural Solutions segment include 3M; ICU Medical; Becton, Dickinson; Baxter International; B. Braun; Hospira; Smiths Medical; CR Bard; Integra Life Sciences; and Teleflex. The Company's medical devices sold in the United States are subject to the Federal Food, Drug and Cosmetic Act, as implemented and enforced by the United States Food and Drug Administration.
» More Articles for CFN

Headlines

Articles On GuruFocus.com
Dividend Aristocrats in Focus Part 18 of 54: Becton, Dickinson & Company Oct 14 2014 
Weekly 52-Week Highs Highlight: BDX, DUK, CFN, INFY Oct 12 2014 
No More a Simple Distributor Sep 07 2014 
FPA Crescent Fund Buys CareFusion, Oracle, Health Net, Sells Omnicare, Travelers, Ensco Jul 16 2013 
FPA Crescent Fund Manager Buys 2 New Stocks Jul 12 2013 
How Richard Blum Had the Best-Performing Picks on GuruFocus in the Past Year Dec 13 2012 
First Pacific Advisors Buys ROSE, CFN, HNT, Sells ESV, PETM, WMT Nov 12 2012 
First Pacific Advisors’ Top New Buys Aug 08 2012 
Crescent Fund's Steven Romick Comments on CareFusion Jul 25 2012 
Steven Romick FPA Crescent Fund Quarterly Commentary Jul 25 2012 

More From Other Websites
SHAREHOLDER ALERT: Brower Piven Announces Class Action Lawsuit in Connection With the Sale of... Oct 22 2014
INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Investors of CareFusion Corporation of Class Action... Oct 20 2014
CareFusion downgraded by Stifel Oct 20 2014
CareFusion (CFN) Enters Overbought Territory Oct 15 2014
INVESTOR ALERT: Levi & Korsinsky, LLP Launches Investigation of the Board of Directors of CareFusion... Oct 14 2014
Investor Lawsuit Against Takeover of CareFusion Corporation (CFN) Announced by Shareholders... Oct 13 2014
Wolf Haldenstein Adler Freeman & Herz LLP Announces That a Class Action Has Been Filed Against... Oct 10 2014
SHAREHOLDER ALERT: Brodsky & Smith, LLC Announces Investigation of CareFusion Corporation in... Oct 10 2014
CAREFUSION CORP. INVESTOR ALERT: Faruqi & Faruqi, LLP Announces the Investigation of CareFusion... Oct 10 2014
SHAREHOLDER ALERT: Brower Piven Launches An Investigation Into The Proposed Sale Of CareFusion... Oct 10 2014
CareFusion Stockholders Encouraged to Contact Securities Law Firm about Takeover Oct 10 2014
CareFusion Continues to Grow on Strong Product Lineup Oct 10 2014
[video] Most resilient stocks Oct 10 2014
LAWSUIT ALERT: Andrews & Springer LLC Announces That a Law Firm Has Filed a Class Action Lawsuit... Oct 09 2014
SHAREHOLDER ALERT: Brodsky & Smith, LLC Announces Investigation of CareFusion Corporation in... Oct 08 2014
Today's Market Thorns, Roses, and All Time Highs... Oct 08 2014
Netsmart, CareFusion Collaboration to Bring Medication Management Solutions to Health and Human... Oct 08 2014
Lifshitz & Miller Law Firm Announces Investigation of Altair Nanotechnologies, Inc., CareFusion,... Oct 07 2014
Today's Market Thorns, Roses, and All Time Highs... Oct 07 2014
Stifel: CareFusion Corporation Deal May Have Far-Flung Effects Oct 07 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK